Is DCGO or ACH more profitable?

Accendra Health has a net margin of -39.84% compared to DocGo's net margin of -62.23%. Accendra Health's return on equity of -13.18% beat DocGo's return on equity. Company Net Margins Return on Equity Return on Assets DocGo -62.23% -44.09% -29.14% Accendra Health -39.84% -13.18% 1.65%

Does the media refer more to DCGO or ACH?

In the previous week, Accendra Health had 1 more articles in the media than DocGo. MarketBeat recorded 3 mentions for Accendra Health and 2 mentions for DocGo. DocGo's average media sentiment score of 0.50 beat Accendra Health's score of 0.08 indicating that DocGo is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment DocGo 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Accendra Health 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better valuation and earnings, DCGO or BDSX?

Biodesix has lower revenue, but higher earnings than DocGo. Biodesix is trading at a lower price-to-earnings ratio than DocGo, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio DocGo $322.20M 0.19 -$182.40M -$1.91 N/A Biodesix $88.50M 2.59 -$35.26M -$4.06 N/A

Is DCGO or BDSX more profitable?

Biodesix has a net margin of -26.97% compared to DocGo's net margin of -62.23%. DocGo's return on equity of -44.09% beat Biodesix's return on equity. Company Net Margins Return on Equity Return on Assets DocGo -62.23% -44.09% -29.14% Biodesix -26.97% -1,684.25% -30.75%

Does the media favor DCGO or BDSX?

In the previous week, Biodesix had 6 more articles in the media than DocGo. MarketBeat recorded 8 mentions for Biodesix and 2 mentions for DocGo. Biodesix's average media sentiment score of 0.52 beat DocGo's score of 0.50 indicating that Biodesix is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment DocGo 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Biodesix 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive

Which has better valuation & earnings, INFU or DCGO?

InfuSystem has higher earnings, but lower revenue than DocGo. DocGo is trading at a lower price-to-earnings ratio than InfuSystem, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio InfuSystem $143.34M 1.67 $870K $0.41 28.95 DocGo $322.20M 0.19 -$182.40M -$1.91 N/A

Is INFU or DCGO more profitable?

InfuSystem has a net margin of 1.12% compared to DocGo's net margin of -62.23%. InfuSystem's return on equity of 2.78% beat DocGo's return on equity. Company Net Margins Return on Equity Return on Assets InfuSystem 1.12% 2.78% 1.41% DocGo -62.23% -44.09% -29.14%

Does the media refer more to INFU or DCGO?

In the previous week, InfuSystem had 4 more articles in the media than DocGo. MarketBeat recorded 6 mentions for InfuSystem and 2 mentions for DocGo. InfuSystem's average media sentiment score of 0.77 beat DocGo's score of 0.50 indicating that InfuSystem is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment InfuSystem 2 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive DocGo 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation & earnings, LFMD or DCGO?

LifeMD has higher earnings, but lower revenue than DocGo. DocGo is trading at a lower price-to-earnings ratio than LifeMD, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio LifeMD $194.05M 0.85 $14.35M $0.05 68.00 DocGo $322.20M 0.19 -$182.40M -$1.91 N/A

Is LFMD or DCGO more profitable?

LifeMD has a net margin of 0.10% compared to DocGo's net margin of -62.23%. DocGo's return on equity of -44.09% beat LifeMD's return on equity. Company Net Margins Return on Equity Return on Assets LifeMD 0.10% -150.35% -30.26% DocGo -62.23% -44.09% -29.14%

Does the media prefer LFMD or DCGO?

In the previous week, LifeMD had 13 more articles in the media than DocGo. MarketBeat recorded 15 mentions for LifeMD and 2 mentions for DocGo. DocGo's average media sentiment score of 0.50 beat LifeMD's score of -0.24 indicating that DocGo is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment LifeMD 1 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Neutral DocGo 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation & earnings, JYNT or DCGO?

Joint has higher earnings, but lower revenue than DocGo. DocGo is trading at a lower price-to-earnings ratio than Joint, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Joint $54.90M 2.14 $2.91M $0.23 35.74 DocGo $322.20M 0.19 -$182.40M -$1.91 N/A

Is JYNT or DCGO more profitable?

Joint has a net margin of 5.72% compared to DocGo's net margin of -62.23%. Joint's return on equity of 7.00% beat DocGo's return on equity. Company Net Margins Return on Equity Return on Assets Joint 5.72% 7.00% 2.05% DocGo -62.23% -44.09% -29.14%

DocGo (DCGO) Competitors

$0.62 0.00 (-0.45%)

Closing price 04:00 PM Eastern

Extended Trading

$0.62 0.00 (-0.32%)

As of 04:10 PM Eastern

Compare

DCGO vs. ACH, BDSX, INFU, LFMD, and JYNT

Should you buy DocGo stock or one of its competitors? MarketBeat compares DocGo with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with DocGo include Accendra Health (ACH), Biodesix (BDSX), InfuSystem (INFU), LifeMD (LFMD), and Joint (JYNT). These companies are all part of the "healthcare services" industry.

How does DocGo compare to Accendra Health?

DocGo (NASDAQ:DCGO) and Accendra Health (NYSE:ACH) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, risk, analyst recommendations, valuation, institutional ownership, profitability, media sentiment and earnings.

DocGo has a beta of 0.99, suggesting that its share price is 1% less volatile than the broader market. Comparatively, Accendra Health has a beta of 1.58, suggesting that its share price is 58% more volatile than the broader market.

DocGo has higher earnings, but lower revenue than Accendra Health. DocGo is trading at a lower price-to-earnings ratio than Accendra Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DocGo	$322.20M	0.19	-$182.40M	-$1.91	N/A
Accendra Health	$2.73B	0.08	-$1.10B	-$14.05	N/A

56.4% of DocGo shares are owned by institutional investors. 5.1% of DocGo shares are owned by insiders. Comparatively, 2.3% of Accendra Health shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, Accendra Health had 1 more articles in the media than DocGo. MarketBeat recorded 3 mentions for Accendra Health and 2 mentions for DocGo. DocGo's average media sentiment score of 0.50 beat Accendra Health's score of 0.08 indicating that DocGo is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
DocGo	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Accendra Health	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

DocGo currently has a consensus target price of $2.38, suggesting a potential upside of 280.00%. Accendra Health has a consensus target price of $5.00, suggesting a potential upside of 68.35%. Given DocGo's stronger consensus rating and higher possible upside, analysts clearly believe DocGo is more favorable than Accendra Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DocGo	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
Accendra Health	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.20

Accendra Health has a net margin of -39.84% compared to DocGo's net margin of -62.23%. Accendra Health's return on equity of -13.18% beat DocGo's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DocGo	-62.23%	-44.09%	-29.14%
Accendra Health	-39.84%	-13.18%	1.65%

Summary

DocGo beats Accendra Health on 9 of the 15 factors compared between the two stocks.

How does DocGo compare to Biodesix?

DocGo (NASDAQ:DCGO) and Biodesix (NASDAQ:BDSX) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, analyst recommendations, valuation, profitability, earnings, dividends and media sentiment.

In the previous week, Biodesix had 6 more articles in the media than DocGo. MarketBeat recorded 8 mentions for Biodesix and 2 mentions for DocGo. Biodesix's average media sentiment score of 0.52 beat DocGo's score of 0.50 indicating that Biodesix is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
DocGo	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Biodesix	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

Biodesix has lower revenue, but higher earnings than DocGo. Biodesix is trading at a lower price-to-earnings ratio than DocGo, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DocGo	$322.20M	0.19	-$182.40M	-$1.91	N/A
Biodesix	$88.50M	2.59	-$35.26M	-$4.06	N/A

DocGo has a beta of 0.99, indicating that its share price is 1% less volatile than the broader market. Comparatively, Biodesix has a beta of 0.56, indicating that its share price is 44% less volatile than the broader market.

Biodesix has a net margin of -26.97% compared to DocGo's net margin of -62.23%. DocGo's return on equity of -44.09% beat Biodesix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
DocGo	-62.23%	-44.09%	-29.14%
Biodesix	-26.97%	-1,684.25%	-30.75%

DocGo currently has a consensus price target of $2.38, suggesting a potential upside of 280.00%. Biodesix has a consensus price target of $28.67, suggesting a potential upside of 29.71%. Given DocGo's higher possible upside, analysts clearly believe DocGo is more favorable than Biodesix.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DocGo	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33
Biodesix	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80

56.4% of DocGo shares are owned by institutional investors. Comparatively, 21.0% of Biodesix shares are owned by institutional investors. 5.1% of DocGo shares are owned by insiders. Comparatively, 23.2% of Biodesix shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Biodesix beats DocGo on 8 of the 15 factors compared between the two stocks.

How does DocGo compare to InfuSystem?

InfuSystem (NYSE:INFU) and DocGo (NASDAQ:DCGO) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, dividends, risk, earnings, analyst recommendations, valuation, media sentiment and institutional ownership.

InfuSystem has higher earnings, but lower revenue than DocGo. DocGo is trading at a lower price-to-earnings ratio than InfuSystem, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
InfuSystem	$143.34M	1.67	$870K	$0.41	28.95
DocGo	$322.20M	0.19	-$182.40M	-$1.91	N/A

In the previous week, InfuSystem had 4 more articles in the media than DocGo. MarketBeat recorded 6 mentions for InfuSystem and 2 mentions for DocGo. InfuSystem's average media sentiment score of 0.77 beat DocGo's score of 0.50 indicating that InfuSystem is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
InfuSystem	2 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
DocGo	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

InfuSystem has a beta of 1.42, meaning that its stock price is 42% more volatile than the broader market. Comparatively, DocGo has a beta of 0.99, meaning that its stock price is 1% less volatile than the broader market.

InfuSystem has a net margin of 1.12% compared to DocGo's net margin of -62.23%. InfuSystem's return on equity of 2.78% beat DocGo's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
InfuSystem	1.12%	2.78%	1.41%
DocGo	-62.23%	-44.09%	-29.14%

71.1% of InfuSystem shares are held by institutional investors. Comparatively, 56.4% of DocGo shares are held by institutional investors. 10.8% of InfuSystem shares are held by insiders. Comparatively, 5.1% of DocGo shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

InfuSystem currently has a consensus target price of $16.67, indicating a potential upside of 40.41%. DocGo has a consensus target price of $2.38, indicating a potential upside of 280.00%. Given DocGo's higher possible upside, analysts plainly believe DocGo is more favorable than InfuSystem.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
InfuSystem	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75
DocGo	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

Summary

InfuSystem beats DocGo on 12 of the 14 factors compared between the two stocks.

How does DocGo compare to LifeMD?

LifeMD (NASDAQ:LFMD) and DocGo (NASDAQ:DCGO) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, valuation, risk, analyst recommendations, profitability, institutional ownership, dividends and earnings.

LifeMD has higher earnings, but lower revenue than DocGo. DocGo is trading at a lower price-to-earnings ratio than LifeMD, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LifeMD	$194.05M	0.85	$14.35M	$0.05	68.00
DocGo	$322.20M	0.19	-$182.40M	-$1.91	N/A

In the previous week, LifeMD had 13 more articles in the media than DocGo. MarketBeat recorded 15 mentions for LifeMD and 2 mentions for DocGo. DocGo's average media sentiment score of 0.50 beat LifeMD's score of -0.24 indicating that DocGo is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
LifeMD	1 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Neutral
DocGo	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

35.5% of LifeMD shares are owned by institutional investors. Comparatively, 56.4% of DocGo shares are owned by institutional investors. 17.2% of LifeMD shares are owned by company insiders. Comparatively, 5.1% of DocGo shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

LifeMD has a net margin of 0.10% compared to DocGo's net margin of -62.23%. DocGo's return on equity of -44.09% beat LifeMD's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LifeMD	0.10%	-150.35%	-30.26%
DocGo	-62.23%	-44.09%	-29.14%

LifeMD presently has a consensus target price of $8.14, indicating a potential upside of 139.50%. DocGo has a consensus target price of $2.38, indicating a potential upside of 280.00%. Given DocGo's higher possible upside, analysts plainly believe DocGo is more favorable than LifeMD.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LifeMD	2 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.60
DocGo	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

LifeMD has a beta of 2.02, meaning that its share price is 102% more volatile than the broader market. Comparatively, DocGo has a beta of 0.99, meaning that its share price is 1% less volatile than the broader market.

Summary

LifeMD beats DocGo on 9 of the 15 factors compared between the two stocks.

How does DocGo compare to Joint?

Joint (NASDAQ:JYNT) and DocGo (NASDAQ:DCGO) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, valuation, dividends, media sentiment, risk, profitability and institutional ownership.

Joint has a net margin of 5.72% compared to DocGo's net margin of -62.23%. Joint's return on equity of 7.00% beat DocGo's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Joint	5.72%	7.00%	2.05%
DocGo	-62.23%	-44.09%	-29.14%

Joint has higher earnings, but lower revenue than DocGo. DocGo is trading at a lower price-to-earnings ratio than Joint, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Joint	$54.90M	2.14	$2.91M	$0.23	35.74
DocGo	$322.20M	0.19	-$182.40M	-$1.91	N/A

Joint has a beta of 1.1, indicating that its stock price is 10% more volatile than the broader market. Comparatively, DocGo has a beta of 0.99, indicating that its stock price is 1% less volatile than the broader market.

Joint currently has a consensus price target of $18.00, indicating a potential upside of 118.98%. DocGo has a consensus price target of $2.38, indicating a potential upside of 280.00%. Given DocGo's stronger consensus rating and higher probable upside, analysts clearly believe DocGo is more favorable than Joint.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Joint	0 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
DocGo	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

76.9% of Joint shares are owned by institutional investors. Comparatively, 56.4% of DocGo shares are owned by institutional investors. 30.2% of Joint shares are owned by company insiders. Comparatively, 5.1% of DocGo shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, DocGo had 1 more articles in the media than Joint. MarketBeat recorded 2 mentions for DocGo and 1 mentions for Joint. DocGo's average media sentiment score of 0.50 beat Joint's score of 0.00 indicating that DocGo is being referred to more favorably in the news media.

Company	Overall Sentiment
Joint	Neutral
DocGo	Positive

Summary

Joint beats DocGo on 9 of the 15 factors compared between the two stocks.

Get DocGo News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DCGO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

DCGO vs. The Competition

Export

Metric	DocGo	Healthcare Providers & Services Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$61.99M	$9.85B	$6.93B	$12.84B
Dividend Yield	N/A	2.56%	2.60%	9.78%
P/E Ratio	N/A	25.26	281.16	25.42
Price / Sales	0.19	5.41	591.75	95.36
Price / Cash	11.35	125.06	71.79	50.79
Price / Book	0.49	5.17	12.86	6.06
Net Income	-$182.40M	$312.25M	$3.49B	$348.34M
7 Day Performance	-6.28%	0.00%	2.64%	3.03%
1 Month Performance	6.31%	-2.37%	-2.64%	-3.04%
1 Year Performance	-55.67%	23.80%	76.00%	20.65%

DocGo Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
DCGO DocGo	3.4524 of 5 stars	$0.63 -0.4%	$2.38 +280.0%	-55.2%	$61.99M	$322.20M	N/A	3,568
ACH Accendra Health	3.6407 of 5 stars	$3.10 -7.2%	$5.00 +61.3%	N/A	$237.41M	$2.72B	N/A	6,500	News Coverage Upcoming Earnings
BDSX Biodesix	3.3956 of 5 stars	$21.20 -0.6%	$28.33 +33.6%	+169.3%	$219.55M	$96.10M	N/A	220	News Coverage Earnings Report Analyst Forecast Gap Down
INFU InfuSystem	4.7492 of 5 stars	$9.14 -0.5%	$15.00 +64.1%	+100.2%	$184.46M	$142.40M	152.36	410	News Coverage Analyst Forecast
LFMD LifeMD	3.1407 of 5 stars	$3.50 -3.8%	$9.14 +161.2%	-68.9%	$169.27M	$193.33M	70.01	230	Trending News Earnings Report Analyst Forecast Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:DCGO) was last updated on 8/6/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

DocGo (DCGO) Competitors

DCGO vs. ACH, BDSX, INFU, LFMD, and JYNT

How does DocGo compare to Accendra Health?

Summary

How does DocGo compare to Biodesix?

Summary

How does DocGo compare to InfuSystem?

Summary

How does DocGo compare to LifeMD?

Summary

How does DocGo compare to Joint?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DCGO vs. The Competition

DocGo Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

DocGo (DCGO) Competitors

DCGO vs. ACH, BDSX, INFU, LFMD, and JYNT

How does DocGo compare to Accendra Health?

Which has more risk and volatility, DCGO or ACH?

Which has stronger valuation and earnings, DCGO or ACH?

Do insiders & institutionals have more ownership in DCGO or ACH?

Does the media refer more to DCGO or ACH?

Do analysts prefer DCGO or ACH?

Is DCGO or ACH more profitable?

Summary

How does DocGo compare to Biodesix?

Does the media favor DCGO or BDSX?

Which has better valuation and earnings, DCGO or BDSX?

Which has more risk and volatility, DCGO or BDSX?

Is DCGO or BDSX more profitable?

Do analysts rate DCGO or BDSX?

Do insiders & institutionals hold more shares of DCGO or BDSX?

Summary

How does DocGo compare to InfuSystem?

Which has better valuation & earnings, INFU or DCGO?

Does the media refer more to INFU or DCGO?

Which has more risk & volatility, INFU or DCGO?

Is INFU or DCGO more profitable?

Do insiders & institutionals hold more shares of INFU or DCGO?

Do analysts recommend INFU or DCGO?

Summary

How does DocGo compare to LifeMD?

Which has stronger valuation & earnings, LFMD or DCGO?

Does the media prefer LFMD or DCGO?

Do institutionals & insiders believe in LFMD or DCGO?

Is LFMD or DCGO more profitable?

Do analysts rate LFMD or DCGO?

Which has more volatility & risk, LFMD or DCGO?

Summary

How does DocGo compare to Joint?

Is JYNT or DCGO more profitable?

Which has higher valuation & earnings, JYNT or DCGO?

Which has more risk and volatility, JYNT or DCGO?

Do analysts prefer JYNT or DCGO?

Do institutionals & insiders hold more shares of JYNT or DCGO?

Does the media prefer JYNT or DCGO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DCGO vs. The Competition

DocGo Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools